Alnylam Pharmaceuticals Inc (ALNY)vsNektar Therapeutics (NKTR)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
NKTR
Nektar Therapeutics
$72.08
-1.21%
HEALTHCARE · Cap: $2.07B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 6624% more annual revenue ($3.71B vs $55.23M). ALNY leads profitability with a 8.5% profit margin vs -297.1%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
NKTR
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for NKTR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Growing faster than its price suggests
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Trading at 16.3x book value
0.0% earnings growth
Weak financial health signals
ROE of -217.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : NKTR
The strongest argument for NKTR centers on PEG Ratio. PEG of 0.31 suggests the stock is reasonably priced for its growth.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : NKTR
The primary concerns for NKTR are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while NKTR is a turnaround play — different risk/reward profiles.
NKTR carries more volatility with a beta of 1.23 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 28/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Nektar Therapeutics
HEALTHCARE · BIOTECHNOLOGY · USA
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?